{
    "organizations": [],
    "uuid": "f47d3e462d358678cb46a6187cfbb7442706ea9b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-teva-canada-announces-launch-of-te/brief-teva-canada-announces-launch-of-teva-cyclosporine-ophthalmic-emulsion-idUSASC0A1HA",
    "ord_in_thread": 0,
    "title": "BRIEF-Teva Canada Announces Launch Of Teva-Cyclosporine Ophthalmic Emulsion",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10, 2018 / 1:23 PM / Updated 29 minutes ago BRIEF-Teva Canada Announces Launch Of Teva-Cyclosporine Ophthalmic Emulsion Reuters Staff 1 Min Read\nMay 10 (Reuters) - Teva Pharmaceutical Industries Ltd :\n* TEVA CANADA ANNOUNCES THE LAUNCH OF TEVA-CYCLOSPORINE® OPHTHALMIC EMULSION, THE FIRST GENERIC VERSION OF RESTASIS® IN CANADA FOR THE TREATMENT OF DRY EYE DISEASE\n* TEVA CANADA LIMITED - LAUNCH OF TEVA-CYCLOSPORINE OPHTHALMIC EMULSION, 0.05% W/V IN CANADA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-05-10T16:22:00.000+03:00",
    "crawled": "2018-05-10T16:41:44.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "pm",
        "updated",
        "minute",
        "ago",
        "canada",
        "announces",
        "launch",
        "ophthalmic",
        "emulsion",
        "reuters",
        "staff",
        "min",
        "read",
        "may",
        "reuters",
        "teva",
        "pharmaceutical",
        "industry",
        "ltd",
        "teva",
        "canada",
        "announces",
        "launch",
        "ophthalmic",
        "emulsion",
        "first",
        "generic",
        "version",
        "canada",
        "treatment",
        "dry",
        "eye",
        "disease",
        "teva",
        "canada",
        "limited",
        "launch",
        "ophthalmic",
        "emulsion",
        "canada",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}